References
- Kumar S. Solitary plasmacytoma: is radiation therapy sufficient? Am J Hematol. 2008;83:695–696.
- Ntanasis-Stathopoulos I, Gavriatopoulou M, Eleftherakis-Papaiakovou E, et al. Rare manifestations of extramedullary myeloma: testicular plasmacytomas. Leuk Lymphoma 2017 [Dec 7]; [3 p.]. DOI: 10.1080/10428194.2017.1410887
- Dores GM, Landgren O, McGlynn KA, et al. Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol. 2009;144:86–94.
- Goyal G, Gonsalves WI, Go RS, et al. Clinical features and outcomes of plasmacytoma in the United States: analysis using the national cancer data base. Blood. 2016;128:3249–3249.
- Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29:3805–3812.
- Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127:971–976.
- Hill QA, Rawstron AC, de Tute RM, et al. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124:1296–1299.
- Paiva B, Chandia M, Vidriales MB, et al. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014;124:1300–1303.
- Fouquet G, Guidez S, Herbaux C, et al. Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma. Clin Cancer Res. 2014;20:3254–3260.
- Kridel R, Telio D, Villa D, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176:210–221.
- Wong KY, Ballard ET, Strayer FH, et al. Clinical and occult testicular leukemia in long-term survivors of acute lymphoblastic leukemia. J Pediatr. 1980;96:569–574.
- Wellwood J, Taylor K, Wright S, et al. Relapsed plasma cell leukaemia presenting with aggressive extramedullary plasmacytomas in the meninges and testis-a missed opportunity for induction CNS prophylaxis. Leuk Lymphoma. 2002;43:893–896.
- Dave DS, Leppert JT, Rajfer J. Is the testis a chemo-privileged site? Is there a blood-testis barrier? Rev Urol. 2007;9:28–32.
- Khan M, Rajarubendra N, Azer S, et al. Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: case report and review of the literature. Urol Ann. 2015;7:530–533.
- Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117:4468–4474.
- Krause S, Hillengass J, Goldschmidt H, et al. Radiotherapy of solitary plasmacytoma. Ann Hematol. 2011;90:1093–1097.
- Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210–217.
- Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50:113–120.
- Li QW, Niu SQ, Wang HY, et al. Radiotherapy alone is associated with improved outcomes over surgery in the management of solitary plasmacytoma. Asian Pac J Cancer Prev. 2015;16:3741–3745.
- Muchtar E, Raanani P, Yeshurun M, et al. Myeloma in scar tissue–an underreported phenomenon or an emerging entity in the novel agents' era? A single center series. Acta Haematol. 2014;132:39–44.
- Billecke L, Murga Penas EM, May AM, et al. Cytogenetics of extramedullary manifestations in multiple myeloma. Br J Haematol. 2013;161:87–94.